The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

A Hepatitis Necessity: Quitting Alcohol

Back to News Homepage

Next

VA Model Improves Hep C Care

Two Modes of Action Explains Daclatasvir’s Potency

February 26, 2013

Print this page

Although still in development, Daclatasvir appears to cause the fastest decline in Hepatitis C viral load seen to date. A combined effort between mathematicians, clinicians and scientists has found that this drug has two, simultaneous modes of action.

New Study On Hepatitis C Drug Treatment in Vivo and in Vitro

Feb. 18, 2013 — Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs. An interdisciplinary effort by mathematical modelers, clinicians and molecular virologists has revealed that daclatasvir has two main modes of action against HCV and also yields a new, more accurate estimate of the HCV half-life.

Results of the NS5A study are published in the Proceedings of the National Academy of Sciences (PNAS) on February 18th, 2013.

Continue reading this entire article:
http://www.sciencedaily.com/releases/2013/02/130218164128.htm

7 Comments
Share
Share

Previous

A Hepatitis Necessity: Quitting Alcohol

Back to News Homepage

Next

VA Model Improves Hep C Care

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.

  • Kevin

    It works very fast. I’m in a study group with Bristol Myers HCV all oral medicines. Before the Daclatasvir and the two other drugs my viral load was 5 million. Five hours later after the meds it was down to 363 thousand. Today, day 34 I’m undetectable. Lets see if I stay undetectable when the meds are stopped on April 23, 2013.

    • pam leach

      Wow Kevin…that’s great! It’s amazing in fact! I don’t know much about this drug..or this study. It this an interferon-based treatment? I hope not! As a recipient of 2 failed treatments, I’m not a candidate for any interferon-based treatments.

      I’m also wondering…what were the side effects of this medication? This is very exciting indeed!!

      Pam L

      Maine11

      • primo!

        i had no side effects from daclatasvir + asunaprevir. only interferon and ribavirin make the problems.

    • Artur

      Woww!! Good luck Kevin, keeping faith! from Brasil.

    • Punawala

      Thank you Kevin for your hopeful information. It is indeed a great news for every one of us suffering from HCV. But the question lies, how ling will it take to bring the medicine to the market? and will it be affordable unlike those Interferron and Rabi based?

  • ritchie

    This is interesting and very hopeful. I just hope it doesn’t turn out like the previous meds. I relapsed 11 years after a sustained viral response with ribavirin and interferon.

  • primo!

    hello from germany, sorry for my english. i finished my study in januar 2013 with daclatasvir, asunaprevir, interferon and ribavirin. the results after 4 weeks end of treatment –> hcv undetected !!!